Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic β cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by " tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing β cells from endogenous progenitors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 488-499 |
| Number of pages | 12 |
| Journal | Immunity |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2010 |
Funding
This work was supported in part by the National Institutes of Health (NIH) Career Award 1K08DK070029 (X.L.), the Type 1 Diabetes Pathfinder Award DP2DK083099 (X.L.), and the Juvenile Diabetes Research Foundation Regular Research Grant 1-2007-1005 (S.D.M and X.L.).
Keywords
- Cellimmuno
- Humdisease
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
